|View printer-friendly version|
|PLASMATECH BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits|
Other Events, Financial Statements and Exhibits
Item 8.01. Other Events
On December 24, 2014, PlasmaTech Biopharmaceuticals, Inc. (the "Company") issued a press release announcing the closing of its previously announced underwritten public offering of 3,500,000 shares of the Company's common stock, and warrants to purchase up to an aggregate 3,500,000 shares of the Company's common stock, at an offering price of $4.00 per share and $0.01 per warrant. The warrants have a per share exercise price of $5.00, are exercisable immediately, and expire 5 years from the date of issuance.
The gross proceeds to the Company from this offering are $14.035 million, before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares and warrants in the offering were sold by the Company.
The Company has also granted the underwriter a 45-day option to purchase up to an additional 525,000 shares of common stock and/or 525,000 warrants to cover over-allotments, if any.
A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
99.1 Press Release, dated December 24, 2014, entitled "PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering"